Product Pathways - Protein Folding
17-AAG #8132
- Molecular Formula:
- C31H43N3O8
- Molecular Weight:
- 585.70 g/mol
- Purity:
- >99%
Directions for Use
17-AAG is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 500 μg in 853.7 μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 0.1-1 μM for 4-24 hours. Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL. Maximum solubility in plain water estimated to be about 20-50 μM.
Western Blotting
Western blot analysis of extracts from LNCaP cells, untreated (-) or treated with 17-AAG (1 μM, 24 hr), using Akt (pan) (11E7) Rabbit mAb #4685 (upper) and β-Actin (13E5) Rabbit mAb #4970 (lower).
Structure
Chemical structure of 17-AAG (17-Demethoxy-17-allyaminogeldanmycin)
Background
17-AAG is a semi-synthetic derivative of geldanamycin, demonstrating greater stability than its parent compound (1). It binds specifically to heat shock protein HSP90 in a manner similar to geldanamycin, but with weaker binding (1). Through specific binding with HSP90, 17-AAG has been shown to decrease levels of many proteins including androgen receptor (AR), HER2, and Akt, while increasing levels of HSP90 in prostate cancer cell lines (2). 17-AAG binds to a conserved pocket in the HSP90 family of chaperone proteins and this occupation causes the degradation of several signaling proteins (2).
- Schulte, T.W. and Neckers, L.M. (1998) Cancer Chemother Pharmacol 42, 273-9.
- Solit, D.B. et al. (2002) Clin Cancer Res 8, 986-93.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
